These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25102091)

  • 1. Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.
    Neogi U; Rao SD; Bontell I; Verheyen J; Rao VR; Gore SC; Soni N; Shet A; Schülter E; Ekstrand ML; Wondwossen A; Kaiser R; Madhusudhan MS; Prasad VR; Sonnerborg A
    AIDS; 2014 Sep; 28(15):2319-22. PubMed ID: 25102091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness.
    van Domselaar R; Njenda DT; Rao R; Sönnerborg A; Singh K; Neogi U
    J Virol; 2019 May; 93(9):. PubMed ID: 30760577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa.
    Neogi U; Engelbrecht S; Claassen M; Jacobs GB; van Zyl G; Preiser W; Sonnerborg A
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):80-4. PubMed ID: 26413747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PTAP sequence duplication in HIV-1 subtype C Gag p6 in drug-naive subjects of India and South Africa.
    Sharma S; Aralaguppe SG; Abrahams MR; Williamson C; Gray C; Balakrishnan P; Saravanan S; Murugavel KG; Solomon S; Ranga U
    BMC Infect Dis; 2017 Jan; 17(1):95. PubMed ID: 28118816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.
    Aralaguppe SG; Winner D; Singh K; Sarafianos SG; Quiñones-Mateu ME; Sönnerborg A; Neogi U
    J Med Virol; 2017 Jan; 89(1):106-111. PubMed ID: 27328744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PYRE insertion within HIV-1 subtype C p6-Gag functions as an ALIX-dependent late domain.
    Chaturbhuj D; Patil A; Gangakhedkar R
    Sci Rep; 2018 Jun; 8(1):8917. PubMed ID: 29891975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.
    Giandhari J; Basson AE; Coovadia A; Kuhn L; Abrams EJ; Strehlau R; Morris L; Hunt GM
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):776-82. PubMed ID: 25919760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors?
    Kletenkov K; Hoffmann D; Böni J; Yerly S; Aubert V; Schöni-Affolter F; Struck D; Verheyen J; Klimkait T;
    J Antimicrob Chemother; 2017 Mar; 72(3):866-875. PubMed ID: 27999036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor.
    Ho SK; Perez EE; Rose SL; Coman RM; Lowe AC; Hou W; Ma C; Lawrence RM; Dunn BM; Sleasman JW; Goodenow MM
    AIDS; 2009 Aug; 23(13):1631-40. PubMed ID: 19625947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations.
    Banke S; Lillemark MR; Gerstoft J; Obel N; Jørgensen LB
    J Virol; 2009 Sep; 83(17):8916-24. PubMed ID: 19515784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.
    Coetzer M; Ledingham L; Diero L; Kemboi E; Orido M; Kantor R
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29098809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.
    Sutherland KA; Ghosn J; Gregson J; Mbisa JL; Chaix ML; Cohen Codar I; Delfraissy JF; Delaugerre C; Gupta RK
    J Antimicrob Chemother; 2015 Jan; 70(1):243-8. PubMed ID: 25228587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.
    Kiguoya MW; Mann JK; Chopera D; Gounder K; Lee GQ; Hunt PW; Martin JN; Ball TB; Kimani J; Brumme ZL; Brockman MA; Ndung'u T
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28424286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility.
    Watanabe SM; Simon V; Durham ND; Kemp BR; Machihara S; Kemal KS; Shi B; Foley B; Li H; Chen BK; Weiser B; Burger H; Anastos K; Chen C; Carter CA
    Retrovirology; 2016 Sep; 13(1):64. PubMed ID: 27600154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
    Rossi AH; Rocco CA; Mangano A; Sen L; Aulicino PC
    AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1056-60. PubMed ID: 23458243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes.
    Li G; Verheyen J; Theys K; Piampongsant S; Van Laethem K; Vandamme AM
    Retrovirology; 2014 Sep; 11():79. PubMed ID: 25253273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.
    Kozísek M; Henke S; Sasková KG; Jacobs GB; Schuch A; Buchholz B; Müller V; Kräusslich HG; Rezácová P; Konvalinka J; Bodem J
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4320-30. PubMed ID: 22644035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.